Literature DB >> 3021954

Reversible and irreversible binding of beta-funaltrexamine to mu, delta and kappa opioid receptors in guinea pig brain membranes.

S W Tam, L Y Liu-Chen.   

Abstract

The effect of beta-funaltrexamine (beta-FNA), an irreversible mu receptor blocker in isolated tissue bioassays, on mu, kappa and delta opioid receptor binding and the binding of beta-[3H]FNA were determined in guinea pig brain membranes. beta-FNA inhibited the binding of mu, kappa and delta opioid ligands to their receptors with Ki values of 2.2, 14 and 78 nM, respectively. Pretreatment of brain membranes with beta-FNA (less than 2 microM) followed by extensive washing inhibited mu binding and to a lesser degree delta binding, without changing kappa binding. The extent of the irreversible inhibition was dependent on the concentration of beta-FNA, and this inhibition on mu binding could be observed with as little as 1 nM beta-FNA. The irreversible inhibition of mu binding by beta-FNA pretreatment was due to a decrease in the number of binding sites with little change in Kd, and was more pronounced in the presence of increasing concentrations of NaCl. Specific binding of beta-[3H]FNA to opioid receptors was demonstrated. The rate of specific binding with 2 nM beta-[3H]FNA was rapid in the initial 10 min and did not reach maximum in 90 min. The dissociation of bound beta-[3H]FNA (5 nM added) by the addition of excess unlabeled naloxone reached maximum at 30 min with approximately 35% of specifically bound beta-[3H]FNA remaining. Mu opioids were most effective in preventing specific binding of beta-[3H]FNA when added before beta-[3H]FNA. Opioids added 1 hr after 2 nM beta-[3H]FNA could displace maximally only 70 to 75% of specific binding.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3021954

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Structure-based design, synthesis, and biochemical and pharmacological characterization of novel salvinorin A analogues as active state probes of the kappa-opioid receptor.

Authors:  Feng Yan; Ruslan V Bikbulatov; Viorel Mocanu; Nedyalka Dicheva; Carol E Parker; William C Wetsel; Philip D Mosier; Richard B Westkaemper; John A Allen; Jordan K Zjawiony; Bryan L Roth
Journal:  Biochemistry       Date:  2009-07-28       Impact factor: 3.162

2.  Use of a mu-antisense oligodeoxynucleotide as a mu opioid receptor noncompetitive antagonist in vivo.

Authors:  X H Chen; L Y Liu-Chen; R J Tallarida; E B Geller; J K de Riel; M W Adler
Journal:  Neurochem Res       Date:  1996-11       Impact factor: 3.996

3.  K303⁶·⁵⁸ in the μ opioid (MOP) receptor is important in conferring selectivity for covalent binding of β-funaltrexamine (β-FNA).

Authors:  Kelly M DiMattio; Chongguang Chen; Lei Shi; Lee-Yuan Liu-Chen
Journal:  Eur J Pharmacol       Date:  2014-12-04       Impact factor: 4.432

4.  Discovery of dermorphin-based affinity labels with subnanomolar affinity for mu opioid receptors.

Authors:  Bhaswati Sinha; Zhengyu Cao; Thomas F Murray; Jane V Aldrich
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

5.  Alkylation with beta-funaltrexamine suggests differences between mu-opioid receptor systems in guinea-pig brain and myenteric-plexus.

Authors:  T G Franklin; J R Traynor
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

6.  Exploring the putative mechanism of allosteric modulations by mixed-action kappa/mu opioid receptor bitopic modulators.

Authors:  Huiqun Wang; Danni Cao; James C Gillespie; Rolando E Mendez; Dana E Selley; Lee-Yuan Liu-Chen; Yan Zhang
Journal:  Future Med Chem       Date:  2021-02-16       Impact factor: 3.808

7.  Long-term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox.

Authors:  Joshua C Zamora; Hudson R Smith; Elaine M Jennings; Teresa S Chavera; Varun Kotipalli; Aleasha Jay; Stephen M Husbands; Alex Disney; Kelly A Berg; William P Clarke
Journal:  Pharmacol Res Perspect       Date:  2021-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.